SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Shinoda J) "

Sökning: WFRF:(Shinoda J)

  • Resultat 1-5 av 5
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • 2017
  • swepub:Mat__t
  •  
2.
  • Ruilope, LM, et al. (författare)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • Tidskriftsartikel (refereegranskat)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
3.
  • Vardelle, Armelle, et al. (författare)
  • Erratum to The 2016 Thermal Spray Roadmap
  • 2017
  • Ingår i: Journal of thermal spray technology (Print). - : Springer Science and Business Media LLC. - 1059-9630 .- 1544-1016. ; 26:5, s. 985-986
  • Tidskriftsartikel (refereegranskat)
  •  
4.
  • Vardelle, Armelle, et al. (författare)
  • The 2016 Thermal Spray Roadmap
  • 2016
  • Ingår i: Journal of thermal spray technology (Print). - : Springer Science and Business Media LLC. - 1059-9630 .- 1544-1016. ; 25:8, s. 1376-1440
  • Tidskriftsartikel (refereegranskat)abstract
    • Considerable progress has been made over the last decades in thermal spray technologies, practices and applications. However, like other technologies, they have to continuously evolve to meet new problems and market requirements. This article aims to identify the current challenges limiting the evolution of these technologies and to propose research directions and priorities to meet these challenges. It was prepared on the basis of a collection of short articles written by experts in thermal spray who were asked to present a snapshot of the current state of their specific field, give their views on current challenges faced by the field and provide some guidance as to the R&D required to meet these challenges. The article is divided in three sections that deal with the emerging thermal spray processes, coating properties and function, and biomedical, electronic, aerospace and energy generation applications. © 2016, ASM International.
  •  
5.
  • Song, Donguk, et al. (författare)
  • Polarization Accuracy Verification of the Chromospheric LAyer SpectroPolarimeter
  • 2022
  • Ingår i: Solar Physics. - : Springer Science and Business Media LLC. - 0038-0938 .- 1573-093X. ; 297:10
  • Tidskriftsartikel (refereegranskat)abstract
    • We have developed an advanced UV spectropolarimeter called Chromospheric LAyer SpectroPolarimeter (CLASP2), aimed at achieving very high accuracy measurements (<0.1% at 3σ) of the linear (Q/I and U/I) and circular (V/I) polarizations of the Mg II h and k lines (280 nm). CLASP2 was launched on board a NASA sounding rocket on April 11, 2019. It successfully detected the full Stokes vector in an active-region plage and in the quiet Sun near the limb across the Mg II h and k lines for the first time. To verify the polarization characteristics of CLASP2, the response matrix is estimated by combining the results obtained from the preflight calibration on the ground, with the results of the inflight calibration acquired at the solar-disk center. We find that the response matrix of CLASP2 in the Mg II h and k lines is notably close to an ideal response matrix, i.e., the scale factor and the crosstalk terms are close to 1 and 0, respectively. Moreover, the uncertainty of each Stokes parameter estimated by the repeatability of the measurements is verified to be within the required tolerance. Based on our investigation, we conclude that CLASP2 achieves 0.1% polarization accuracy at a 3σ3σ level.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-5 av 5

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy